Skip to content

LSD research published in 2025

Page 5 of 6: studies 81 to 100 of 118, newest first. Back to the LSD overview

Studies

Sporadic use of classic psychedelics and neuropsychological performance: A cross-sectional analysis.

Progress in Neuro-Psychopharmacology and Biological Psychiatry April 2, 2025 Simon Reiche, Tim Hirschfeld, Anna Lena Gröticke et al. 5 citations

Evidence on the neuropsychological consequences of classic psychedelics like psilocybin, LSD, and ayahuasca is conflicting, and little is known about how sporadic use of psychedelics under naturalistic conditions may affect cognitive functioning. Given the growing interest in the therapeutic potential of psychedelics and the rise in non-medical use, further exploration into their...

Comparing Substance Use Consequences between Serotonergic Psychedelics, MDMA, and other Drugs of Abuse Among United States Adults with History of Psychiatric Illness

International Journal of Mental Health and Addiction April 1, 2025 Joshua C. Black, Nicole Schow, Hannah L. Burkett et al. 3 citations

Psychedelic-assisted therapy could transform treating psychiatric illness, but harms from exacerbating substance use disorder (SUD) among adults with psychiatric illness using psychedelics have not been studied. A cross-sectional survey in the US was used to test whether Drug Abuse Screening Test scores (DAST-10, validated instrument predicting SUD) were more severe when psychiatric illnesses...

Synthesis and analytical characterization of 1-(2-thienoyl)-6-allyl-nor-d-lysergic acid diethylamide (1T-AL-LAD).

Drug Testing and Analysis April 1, 2025 Yuki Okada, Hiroki Segawa, Tadashi Yamamuro et al. 6 citations

Lysergic acid diethylamide (LSD) analogs have emerged as new psychoactive substances (NPS) since the mid-2010s, and new compounds continue to emerge for recreational use. Since the end of 2023, "1D-AL-LAD" appeared on X (formerly Twitter) and other websites. As for the compound "1D-LSD" (which also has "1D" in the name), several studies show that the ingredient of seized blotter paper printed...

DOI: 10.1002/dta.3747 (opens in new tab) Full text (opens in new tab) 1d‐al‐lad Chemical synthesis New psychoactive substances Chemical analysis +3

Analytical and behavioral characterization of 1-hexanoyl-LSD (1H-LSD).

Drug Testing and Analysis April 1, 2025 Simon D. Brandt, Pierce V. Kavanagh, Sarah Gare et al. 4 citations

The development of lysergic acid diethylamide (LSD) derivatives and analogs continues to inform the design of novel receptor probes and potentially new medicines. On the other hand, a number of newly developed LSD derivatives have also emerged as recreational drugs, leading to reports of their detection in some countries. One position in the ergoline scaffold of LSD that is frequently targeted...

DOI: 10.1002/dta.3767 (opens in new tab) Full text (opens in new tab) LSD Psychedelics hallucinogens Acid research Head‐twitch response +6

Large-scale brain connectivity changes following the administration of lysergic acid diethylamide, d-amphetamine, and 3,4-methylenedioxyamphetamine.

Molecular Psychiatry April 1, 2025 Mihai Avram, Lydia Fortea, Lea Wollner et al. 26 citations

Psychedelics have recently attracted significant attention for their potential to mitigate symptoms associated with various psychiatric disorders. However, the precise neurobiological mechanisms responsible for these effects remain incompletely understood. A valuable approach to gaining insights into the specific mechanisms of action involves comparing psychedelics with substances that have...

DOI: 10.1038/s41380-024-02734-y (opens in new tab) Full text (opens in new tab) Psychedelics hallucinogens Psychoactive drugs Entheogens Brain networks +4

Utilizing Psychedelics to Enhance Well-Being: A Systematic Review

Journal of Psychoactive Drugs March 31, 2025 Samuel Thomson, Nikos Thomacos 11 citations

Psychedelic-assisted therapy is gaining recognition for its potential to enhance human functioning. While most research has focused on psychedelic' therapeutic use for mental illness, this review applies the PERMA Theory of Well-Being to systematically examine their role in enhancing well-being in healthy individuals. The final search of five academic databases was conducted on February 4,...

The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics

Journal of Psychopharmacology March 31, 2025 Tomislav Majić, Timo Torsten Schmidt, Anna Gröticke et al. 4 citations

Background: Classic psychedelics such as psilocybin and lysergic acid diethylamide are anecdotally associated with the phenomenon of “psychedelic afterglow,” a set of predominantly pleasant, temporary psychological effects reported after the acute effects have subsided. Since post-acute effects are crucial for the therapeutic use of psychedelics, an instrument to systematically assess subacute...

Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.

Pharmaceuticals March 29, 2025 Hossein Omidian, Alborz Omidian 5 citations

Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise...

DOI: 10.3390/ph18040499 (opens in new tab) Full text (opens in new tab) LSD Clinical research Pharmacogenetics Serotonin receptors +8

Motivation and retrospective appraisal of psychedelic study participation: a qualitative study in healthy volunteers.

Psychopharmacology March 26, 2025 Laura Ley, Matthias E. Liechti, Anna M Becker et al. 3 citations

Little is known about motives of healthy volunteers to participate in psychedelic trials and how they appraise their study experience retrospectively. This paper explored reasons why healthy people register for psychedelic trials, factors that they considered to contribute to either positive or negative study experiences, and under which circumstances they would seek a psychedelic experience...

LSD reconfigures the frequency-specific network landscape of the human brain

bioRxiv March 24, 2025 Kenneth Shinozuka, Mattia Rosso, Clayton R. Coleman et al. 3 citations preprint

Abstract Lysergic acid diethylamide (LSD) and other psychedelic substances profoundly alter human consciousness. While several studies have demonstrated changes in brain function and connectivity associated with psychedelics, we still have a limited understanding of how LSD reshapes brain networks operating across different frequency bands. In this study, we applied the recently developed...

Psychedelics and autobiographical memory - six open questions.

Psychopharmacology March 17, 2025 Samuli Kangaslampi, Morten P. Lietz 10 citations

Since the earliest LSD research, psychedelics have been claimed to enhance autobiographical memory. Revisiting and processing autobiographical memories has further been suggested to be a major component of the therapeutic action of psychedelics. However, modern psychedelic research has largely neglected autobiographical elements of psychedelic experiences, and many vital questions remain...

Lifetime classic psychedelic use and headaches: A cross-sectional study.

Journal of Psychopharmacology March 12, 2025 Zusanna Bjurenfalk, Alva Cosmo, Otto Simonsson et al. 3 citations

Migraine and cluster headache are two primary headache disorders for which conventional treatments are limited. Classic psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin are potentially promising new treatment candidates for these conditions. The aim of the present study was to investigate the possible relationship between the lifetime use of classic psychedelics...

PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS

Journal of medical & health sciences review. March 11, 2025 Ahmad Daryani, Muhammad Ali, Usman Ul Haq

Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders including treatment-resistant depression, PTSD, and anxiety. These substances mainly affect the serotonergic receptors that involve the regulation of consciousness, perceptions, and cognition. These unique alterations in brain connectome show the...

Side effects of microdosing lysergic acid diethylamide and psilocybin: A systematic review of potential physiological and psychiatric outcomes

Neuropharmacology March 7, 2025 Stefan Modzelewski, Anna Stankiewicz, Napoleon Waszkiewicz et al. 5 citations

This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently and systematically present a description of side effects.

Psychedelics for Cancer Pain and Associated Psychological Distress: A Narrative Review of a Potential Strategy

Cancer Medicine March 1, 2025 Erika Belitzky, Lis Victoria Ravani Carvalho, Melissa Taylor et al. 5 citations

ABSTRACT Purpose To evaluate the current level of evidence for the use of psychedelics for the management of cancer pain and associated psychological distress. Content Pain is a common symptom of cancer and treatment. However, there are high rates of undertreatment of cancer pain due to the complex underlying biology of the condition, and potentially due to a decrease in opioid prescribing in...

Acute Effects and Pharmacokinetics of LSD after Paroxetine or Placebo Pre‐Administration in a Randomized, Double‐Blind, Cross‐Over Phase I Trial

Clinical Pharmacology & Therapeutics February 28, 2025 Lorenz Mueller, Alen Jelusic, Avram Tolev et al. 15 citations

Psychedelics, such as psilocybin and lysergic acid diethylamide (LSD), are being investigated for the treatment of depressive and anxiety disorders, for which concomitant treatment with selective serotonin reuptake inhibitors (SSRIs) is prevalent. The present study investigated the acute response to single doses of LSD (100 μg) after daily administration of paroxetine (10 mg for 7 days,...

DOI: 10.1002/cpt.3618 (opens in new tab) Pharmacokinetics Placebo Double blind Pharmacology +5

BEHAVIORAL AND ELECTROPHYSIOLOGICAL EFFECTS OF LYSERGIC ACID DIETHYLAMIDE (LSD) IN A MOUSE MODEL OF ALCOHOL USE DISORDER (AUD)

The International Journal of Neuropsychopharmacology February 12, 2025 *Danilo De Gregorio, Carolina Giulia Ferroni, Noemi Nicosia et al.

Abstract Introduction Alcohol use disorder (AUD) is a major problem that causes significant health and social problem. Pharmacological treatments for AUD are limited in their effectiveness, and new drugs are required (ref). Recently, the potential use of psychedelics as novel therapies in treating mental diseases has come to the forefront in psychiatry. For instance, lysergic acid diethylamide...

THE PROTOTYPICAL PSYCHEDELIC AGENT LSD PRODUCES RAPID ANTIDEPRESSANT EFFECTS VIA 5-HT2B RECEPTOR ACTIVATION

The International Journal of Neuropsychopharmacology February 12, 2025 Amel Bouloufa, Sarah Delcourte, Renaud Rovera et al.

Abstract Background Recent clinical trials reveal that serotonergic psychedelics, including the prototypical hallucinogen lysergic acid diethylamide (LSD), present a promising potential for treating psychiatric disorders, including treatment-resistant depression. LSD is a potent 5-HT receptors ligand endowed with high affinity for most of all 5-HT subtypes and is regularly used as a valuable...

[Neuroimaging correlates of classical psychedelics effects: A systematic review].

L'Encephale February 1, 2025 Doriane Dost, Amine Benyamina, Laurent Karila

Current scientific literature supports classical psychedelic efficacy in many psychiatric disorders. However, less attention has been given to the neurological effects of these substances. The aim of this medical thesis was to conduct a systematic review examining the neuroimaging correlates of the effects of psychedelics. We performed an electronic research through Medline and Science Direct...

DOI: 10.1016/j.encep.2024.02.007 (opens in new tab) Full text (opens in new tab) LSD Acide lysergique diéthylamide N,N Diméthyltryptamine Psilocybine +4

Multimodal creativity assessments following acute and sustained microdosing of lysergic acid diethylamide.

Psychopharmacology February 1, 2025 Robin J Murphy, Rachael Sumner, Kate Godfrey et al. 9 citations

Enhanced creativity is often cited as an effect of microdosing (taking repeated low doses of a psychedelic drug). There have been recent efforts to validate the reported effects of microdosing, however creativity remains a difficult construct to quantify. The current study aimed to assess microdosing's effects on creativity using a multimodal battery of tests as part of a randomised controlled...